Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy

H. C. Harsha, Antonio Jimeno, Henrik Molina, Anca B. Mlhalas, Michael G. Goggins, Ralph H. Hruban, Richard D. Schulick, Ullas Kamath, Anirban Maitra, Manuel Hidalgo, Akhilesh Pandey

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Pancreatic cancer is one of the most fatal among all solid malignancies. Targeted therapeutic approaches have the potential to transform cancer therapy as exemplified by the success of several tyrosine kinase inhibitors. Prompted by this, comprehensive profiling of tyrosine kinases and their substrates was carried out using a panel of low passage pancreatic cancer cell lines. One of the pancreatic cancer cell lines, P196, which showed dramatic upregulation of tyrosine kinase activity as compared to non-neoplastic cells, was systematically studied using a quantitative proteomic approach called stable isotope labeling with amino acids in cell culture (SILAC). A careful analysis of activated tyrosine kinase pathways revealed aberrant activation of epidermal growth factor receptor pathway in this cell line. Mouse xenograft based studies using EGFR inhibitor erlotinib confirmed EGFR pathway to be responsible for proliferation in these tumors. By a systematic study across low passage pancreatic cancer cell lines and mice carrying pancreatic cancer xenografts, we have demonstrated activated epidermal growth factor receptor as an attractive candidate for targeted therapy in a subset of pancreatic cancers. Further, we propose immunohistochemical labeling of activated EGFR (pEGFR1068) as an efficient screening tool to select patients who are more likely to respond to EGFR inhibitors.

Original languageEnglish
Pages (from-to)4651-4658
Number of pages8
JournalJournal of Proteome Research
Volume7
Issue number11
DOIs
Publication statusPublished - 01-11-2008

Fingerprint

Pancreatic Neoplasms
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Cells
Heterografts
Labeling
Cell Line
Therapeutics
Cell culture
Isotopes
Isotope Labeling
Tumors
Neoplasms
Screening
Chemical activation
Amino Acids
Proteomics
Up-Regulation
Substrates
Cell Culture Techniques

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Chemistry(all)

Cite this

Harsha, H. C., Jimeno, A., Molina, H., Mlhalas, A. B., Goggins, M. G., Hruban, R. H., ... Pandey, A. (2008). Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. Journal of Proteome Research, 7(11), 4651-4658. https://doi.org/10.1021/pr800139r
Harsha, H. C. ; Jimeno, Antonio ; Molina, Henrik ; Mlhalas, Anca B. ; Goggins, Michael G. ; Hruban, Ralph H. ; Schulick, Richard D. ; Kamath, Ullas ; Maitra, Anirban ; Hidalgo, Manuel ; Pandey, Akhilesh. / Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. In: Journal of Proteome Research. 2008 ; Vol. 7, No. 11. pp. 4651-4658.
@article{ec49a1b5d442494faa10fa3d8975ce7f,
title = "Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy",
abstract = "Pancreatic cancer is one of the most fatal among all solid malignancies. Targeted therapeutic approaches have the potential to transform cancer therapy as exemplified by the success of several tyrosine kinase inhibitors. Prompted by this, comprehensive profiling of tyrosine kinases and their substrates was carried out using a panel of low passage pancreatic cancer cell lines. One of the pancreatic cancer cell lines, P196, which showed dramatic upregulation of tyrosine kinase activity as compared to non-neoplastic cells, was systematically studied using a quantitative proteomic approach called stable isotope labeling with amino acids in cell culture (SILAC). A careful analysis of activated tyrosine kinase pathways revealed aberrant activation of epidermal growth factor receptor pathway in this cell line. Mouse xenograft based studies using EGFR inhibitor erlotinib confirmed EGFR pathway to be responsible for proliferation in these tumors. By a systematic study across low passage pancreatic cancer cell lines and mice carrying pancreatic cancer xenografts, we have demonstrated activated epidermal growth factor receptor as an attractive candidate for targeted therapy in a subset of pancreatic cancers. Further, we propose immunohistochemical labeling of activated EGFR (pEGFR1068) as an efficient screening tool to select patients who are more likely to respond to EGFR inhibitors.",
author = "Harsha, {H. C.} and Antonio Jimeno and Henrik Molina and Mlhalas, {Anca B.} and Goggins, {Michael G.} and Hruban, {Ralph H.} and Schulick, {Richard D.} and Ullas Kamath and Anirban Maitra and Manuel Hidalgo and Akhilesh Pandey",
year = "2008",
month = "11",
day = "1",
doi = "10.1021/pr800139r",
language = "English",
volume = "7",
pages = "4651--4658",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "11",

}

Harsha, HC, Jimeno, A, Molina, H, Mlhalas, AB, Goggins, MG, Hruban, RH, Schulick, RD, Kamath, U, Maitra, A, Hidalgo, M & Pandey, A 2008, 'Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy', Journal of Proteome Research, vol. 7, no. 11, pp. 4651-4658. https://doi.org/10.1021/pr800139r

Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. / Harsha, H. C.; Jimeno, Antonio; Molina, Henrik; Mlhalas, Anca B.; Goggins, Michael G.; Hruban, Ralph H.; Schulick, Richard D.; Kamath, Ullas; Maitra, Anirban; Hidalgo, Manuel; Pandey, Akhilesh.

In: Journal of Proteome Research, Vol. 7, No. 11, 01.11.2008, p. 4651-4658.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy

AU - Harsha, H. C.

AU - Jimeno, Antonio

AU - Molina, Henrik

AU - Mlhalas, Anca B.

AU - Goggins, Michael G.

AU - Hruban, Ralph H.

AU - Schulick, Richard D.

AU - Kamath, Ullas

AU - Maitra, Anirban

AU - Hidalgo, Manuel

AU - Pandey, Akhilesh

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Pancreatic cancer is one of the most fatal among all solid malignancies. Targeted therapeutic approaches have the potential to transform cancer therapy as exemplified by the success of several tyrosine kinase inhibitors. Prompted by this, comprehensive profiling of tyrosine kinases and their substrates was carried out using a panel of low passage pancreatic cancer cell lines. One of the pancreatic cancer cell lines, P196, which showed dramatic upregulation of tyrosine kinase activity as compared to non-neoplastic cells, was systematically studied using a quantitative proteomic approach called stable isotope labeling with amino acids in cell culture (SILAC). A careful analysis of activated tyrosine kinase pathways revealed aberrant activation of epidermal growth factor receptor pathway in this cell line. Mouse xenograft based studies using EGFR inhibitor erlotinib confirmed EGFR pathway to be responsible for proliferation in these tumors. By a systematic study across low passage pancreatic cancer cell lines and mice carrying pancreatic cancer xenografts, we have demonstrated activated epidermal growth factor receptor as an attractive candidate for targeted therapy in a subset of pancreatic cancers. Further, we propose immunohistochemical labeling of activated EGFR (pEGFR1068) as an efficient screening tool to select patients who are more likely to respond to EGFR inhibitors.

AB - Pancreatic cancer is one of the most fatal among all solid malignancies. Targeted therapeutic approaches have the potential to transform cancer therapy as exemplified by the success of several tyrosine kinase inhibitors. Prompted by this, comprehensive profiling of tyrosine kinases and their substrates was carried out using a panel of low passage pancreatic cancer cell lines. One of the pancreatic cancer cell lines, P196, which showed dramatic upregulation of tyrosine kinase activity as compared to non-neoplastic cells, was systematically studied using a quantitative proteomic approach called stable isotope labeling with amino acids in cell culture (SILAC). A careful analysis of activated tyrosine kinase pathways revealed aberrant activation of epidermal growth factor receptor pathway in this cell line. Mouse xenograft based studies using EGFR inhibitor erlotinib confirmed EGFR pathway to be responsible for proliferation in these tumors. By a systematic study across low passage pancreatic cancer cell lines and mice carrying pancreatic cancer xenografts, we have demonstrated activated epidermal growth factor receptor as an attractive candidate for targeted therapy in a subset of pancreatic cancers. Further, we propose immunohistochemical labeling of activated EGFR (pEGFR1068) as an efficient screening tool to select patients who are more likely to respond to EGFR inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=58149382070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149382070&partnerID=8YFLogxK

U2 - 10.1021/pr800139r

DO - 10.1021/pr800139r

M3 - Article

C2 - 18821783

AN - SCOPUS:58149382070

VL - 7

SP - 4651

EP - 4658

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 11

ER -

Harsha HC, Jimeno A, Molina H, Mlhalas AB, Goggins MG, Hruban RH et al. Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. Journal of Proteome Research. 2008 Nov 1;7(11):4651-4658. https://doi.org/10.1021/pr800139r